Publications by authors named "E Sonnet"
Introduction: The MiniMed™ 780G system uses an advanced hybrid closed loop algorithm to improve outcomes in people with type 1 diabetes (T1D). The MiniMed™ 780G Glycemic Control and Quality of Life (EQOL) study aimed to provide routine clinical practice data on system effectiveness and associated patient-reported outcomes (PROs) in France.
Methods: Individuals aged ≥ 7 years with T1D were enrolled.
Importance: A major issue in the management of craniopharyngioma-related obesity (CRO) is the ineffectiveness of the current therapeutic approaches.
Objective: To study the efficacy of glucagon-like peptide-1 analogs compared with placebo in adults with obesity CRO.
Design: A double-blind multicenter superiority randomized clinical in trial in two parallel arms.
Article Synopsis
- * Results showed significant improvements in key measures: time in range (TIR) increased by 9.1%, HbA1c decreased by 0.5%, and notable reductions in time spent below and above target levels.
- * The majority of patients (92.7%) continued using the system, and more achieved glycemic goals after one year, although there were some reported cases of severe hypoglycemia and ketoacidosis.
Article Synopsis
- Prolactinomas account for a significant portion of pituitary adenomas, yet the genetic factors behind these tumors remain largely unexplored, prompting a study of hereditary links.
- The study analyzed genetic and clinical data from 506 patients with isolated prolactinomas, discovering that 2.8% carried pathogenic variants in key genes related to tumor predisposition, particularly among those diagnosed before age 30.
- No relevant mutations were found in patients over 30, highlighting the importance of focusing on younger patients and those with a family history when assessing genetic risks for prolactinomas.
Evaluate the impact of the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system on the glucose profile of pregnant women with type 1 diabetes (T1D) and maternal-neonatal complications. From April 2021 to September 2022, pregnant women with T1D treated with the AHCL system were included in an observational multicenter retrospective study. Continuous glucose monitoring parameters were analyzed monthly during pregnancy as well as maternal-neonatal complications.
View Article and Find Full Text PDF